Tetra Bio Pharma

Bioscience firm that's developing cannabinoid-based treatments for chronic pain is slated to move up from TSX Venture Exchange on Aug. 4.
Funds will be used to advance the company’s work on QIXLEEF, a therapy to treat uncontrolled pain in advanced cancer patients that’s in the late-phase drug development stage.
An Ottawa bioscience company is turning to the markets for an injection of capital, announcing plans this week for a bought deal offering
Tetra Bio-Pharma’s shareholders are endorsing the local firm’s plans to accelerate its cannabidiol research efforts as excitement around the market for hemp-based products heats up.
An east-end Ottawa research firm has acquired another pharmaceutical company working in the cannabinoid space, bolstering both its product pipeline and roster of researchers.
Tetra Bio-Pharma raised a few extra million dollars this week, as the Orléans-based firm announced an expansion into the European medical cannabis market.
An Orleans-based cannabinoid drug company announced plans Thursday to raise $8 million in a bought deal offering.
With their expansion plans in high gear, two of the region’s marijuana firms are strengthening their executive teams with several high-profile appointments.
Armed with a new name and fresh funding, a local medical marijuana firm says it hopes to bring its pharmaceutical product to market in early 2018, a company executive says.